In particular, the use of interferon lambda-3 (IFNλ3; IL-28b) as an adjuvant has been demonstrated to significantly enhance specific adaptive immune responses and decrease the levels of inflammatory cytokines, as well as improve protective responses at a high viral challenge dose for influenza (Sabbaghi et al. 2021; Wallace et al. 2021; Mallampalli et al. 2021). This evidence concerns the gene IFNL3 and influenza.